图卡替尼CYP2C8相互作用的PBPK模型预测
研究开发了图卡替尼的生理药动学(PBPK)模型,模拟300 mg每日两次口服后血药浓度,经临床DDI数据验证后能重现单药及联用伊曲康唑、利福平或吉非罗齐的暴露。模型预测与中度CYP2C8抑制剂联用时图卡替尼AUC比值为1.98至3.08倍,据此说明书未建议中度CYP2C8抑制剂剂量调整。
要点
- 图卡替尼PBPK模型经临床DDI数据验证,可重现单药及联用伊曲康唑、利福平或吉非罗齐的暴露。
- 模拟与中度CYP2C8抑制剂联用时,图卡替尼AUC比值范围为1.98至3.08倍。
- 基于上述结果,图卡替尼说明书未建议中度CYP2C8抑制剂联用时调整剂量。
核心结论
- 图卡替尼PBPK模型可预测其作为 perpetrator 或 victim 的DDI风险,预测与中度CYP2C8抑制剂联用时AUC比值1.98至3.08倍,未建议剂量调整。
研究设计与样本
- 基于生理的药动学(PBPK)建模研究,模拟图卡替尼300 mg每日两次口服的单次或多次给药后血浆浓度,并用临床DDI数据验证。
主要发现
- 最终PBPK模型能重现健康受试者单用图卡替尼及联用伊曲康唑、利福平或吉非罗齐时的临床观察血浆浓度。
- 模型还能重现CYP3A4、CYP2C8、CYP2C9、P-gp或MATE1/2-K探针底物的临床观察血浆浓度。
关键数值与推荐
- 模拟与中度CYP2C8抑制剂联用时,图卡替尼AUC比值范围为1.98至3.08倍。
- 基于该AUC比值范围,图卡替尼说明书未建议中度CYP2C8抑制剂联用时调整剂量。
临床怎么用
- 临床药师可参考该PBPK模型预测结果,理解图卡替尼与中度CYP2C8抑制剂联用无需调整剂量的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A physiologically-based pharmacokinetic (PBPK) model was developed to simulate plasma concentrations of tucatinib (TUKYSA®) after single-dose or multiple-dose administration of 300 mg b.i.d. orally. This PBPK model was subsequently applied to support evaluation of drug-drug interaction (DDI) risk as a perpetrator resulting from tucatinib inhibition of CYP3A4, CYP2C8, CYP2C9, P-gp, or MATE1/2-K. The PBPK model was also applied to support evaluation of DDI risk as a victim resulting from co-administration with CYP3A4 or CYP2C8 inhibitors, or a CYP3A4 inducer. After refinement with clinical DDI data, the final PBPK model was able to recover the clinically observed single and multiple-dose plasma concentrations for tucatinib when tucatinib was administered as a single agent in healthy subjects. In addition, the final model was able to recover clinically observed plasma concentrations of tucatinib when administered in combination with itraconazole, rifampin, or gemfibrozil as well as clinically observed plasma concentrations of probe substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, or MATE1/2-K. The PBPK model was then applied to prospectively predict the potential perpetrator or victim DDIs with other substrates, inducers, or inhibitors. To simulate a potential interaction with a moderate CYP2C8 inhibitor, two novel PBPK models representing a moderate CYP2C8 inhibitor and a sensitive CYP2C8 substrate were developed based on the existing PBPK models for gemfibrozil and rosiglitazone, respectively. The simulated population geometric mean area under the curve ratio of tucatinib with a moderate CYP2C8 inhibitor ranged from 1.98- to 3.08-fold, and based on these results, no dose modifications were proposed for moderate CYP2C8 inhibitors for the tucatinib label.
引用
- Templeton IE, Rowland-Yeo K, Jones HM, et al. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib. Clin Pharmacol Ther. 2023. PMID: 37971208. doi:10.1002/cpt.3104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。